टियोट्रोपियम और यूमेक्लिडिनियम और विलैंटेरोल का इंटरैक्शन

Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs.

Therefore, avoid coadministration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs as this may lead to an increase in anticholinergic adverse effects [see Warnings and Precautions (5.4 , 5.5) and Adverse Reactions (6) ].

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions.

In the event of an acute attack, a rapid-acting beta 2 -agonist should be used.

If this occurs, it should be treated immediately with an inhaled short-acting beta 2 -agonist such as albuterol.

Avoid administration of Umeclidinium and Vilanterol ELLIPTA with other anticholinergic-containing drugs.

Therefore, avoid coadministration of Umeclidinium and Vilanterol ELLIPTA with other anticholinergic-containing drugs as this may lead to an increase in anticholinergic adverse effects [see Warnings and Precautions ( 5.9 , 5.10 )] .